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Abstract
Background: Antineoplastic therapy may impair the survival of malignant cells to produce cell death. Consequently, direct
measurement of tumor cell death in vivo is a highly desirable component of therapy response monitoring. We have
previously shown that APOMABH representing the DAB4 clone of a La/SSB-specific murine monoclonal autoantibody is a
malignant cell-death ligand, which accumulates preferentially in tumors in an antigen-specific and dose-dependent manner
after DNA-damaging chemotherapy. Here, we aim to image tumor uptake of APOMABH (DAB4) and to define its biological
correlates.
Methodology/Principal Findings: Brisk tumor cell apoptosis is induced in the syngeneic EL4 lymphoma model after
treatment of tumor-bearing mice with DNA-damaging cyclophosphamide/etoposide chemotherapy. Tumor and normal
organ accumulation of Indium 111 (
111In)-labeled La-specific DAB4 mAb as whole IgG or IgG fragments was quantified by
whole-body static imaging and organ assay in tumor-bearing mice. Immunohistochemical measurements of tumor caspase-
3 activation and PARP-1 cleavage, which are indicators of early and late apoptosis, respectively, were correlated with tumor
accumulation of DAB4. Increased tumor accumulation of DAB4 was associated directly with both the extent of
chemotherapy-induced tumor cell death and DAB4 binding per dead tumor cell. Tumor DAB4 accumulation correlated with
cumulative caspase-3 activation and PARP-1 cleavage as tumor biomarkers of apoptosis and was directly related to the
extended median survival time of tumor-bearing mice.
Conclusions/Significance: Radiolabeled La-specific monoclonal antibody, DAB4, detected dead tumor cells after
chemotherapy, rather than chemosensitive normal tissues of gut and bone marrow. DAB4 identified late apoptotic tumor
cells in vivo. Hence, radiolabeled DAB4 may usefully image responses to human carcinoma therapy because DAB4 would
capture the protracted cell death of carcinoma. We believe that the ability of radiolabeled DAB4 to rapidly assess the
apoptotic tumor response and, consequently, to potentially predict extended survival justifies its future clinical
development as a radioimmunoscintigraphic agent. This article is part I of a two-part series providing proof-of-concept
for the the diagnostic and therapeutic use of a La-specific monoclonal antibody, the DAB4 clone of which is represented by
the registered trademark, APOMABH.
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Introduction
Neoplasia results from an imbalance between rates of cellular
proliferation and survival in a tissue [1]. Successful antineoplastic
treatment controls tumor growth by inhibiting cellular proliferation
and/or survival.Ideally, precisemulti-parametric measures of cellular
proliferation and survival in vivo may enable patient outcomes to be
determined earlier than conventional measures allow [2].
Most patients with metastatic malignancy are not curable, and
may be treated with systemic cytotoxic chemotherapy to palliate
cancer-related symptoms and/or to prolong life. Most cytotoxic
regimens comprise DNA-damaging drugs, and tumor response
rates are generally less than 50%. To know if chemotherapy is
working, patients are usually scanned after two or three cycles (or
six to nine weeks) of treatment with computed tomography (CT) to
assess lesion size by Response Evaluation Criteria in Solid Tumors
(RECIST). Apart from evident clinical improvement, CT evidence
of lack of progression may indicate that treatment is effective and
may be used in the decision to continue treatment. To minimize
patient exposure to potentially toxic and ineffective treatment,
therapy monitoring technologies are being developed [3–6].
Among these technologies,
18F-fluorodeoxyglucose-positron emis-
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acceptance [2,7,8]. However, it should be noted that FDG uptake
in vivo is non-specific and is a composite measure of several
biological processes. For example, FDG may be taken up by
inflammatory as well as neoplastic tissues [9]. Furthermore, loss of
tumor uptake of FDG within hours of treatment of gastro-
intestinal stromal tumor with imatinib [10] or of non-small lung
cancer with gefitinib [11] represents reduced glucose utilization
rather than tumor cell death [9]. In some malignancies, tumor
uptake of FDG may best be considered as a measure of cell
viability rather than as a direct measure of cell death or of the
proliferative status of tumor cells.
An unmet medical need exists for robust, minimally invasive,
and universally applicable measures of early tumor response to
anti-cancer treatment. Molecular imaging methods, in particular,
may yield personalized and real-time assays of biologically
significant processes such as apoptosis. Fusion of PET images
with CT or magnetic resonance images provides precise and
quantitative data, and delivers three-dimensional representations
of the essential anatomic and pathophysiologic heterogeneity of
many tumors [2,12]. Importantly, commercial imperatives are
driving the use of therapy monitoring technologies to streamline
‘‘go/no go’’ decision making in the protracted and costly exercise
of drug development [13]. As stated recently: ‘‘Real-time imaging
of cell death would be a coveted application with which to assess
the efficacy of cytotoxic drugs and, potentially, to monitor the
toxicity of these drugs in normal tissues’’ [14].
Radiolabeled recombinant annexin V, which binds phosphati-
dylserine everted on the exterior surface of apoptotic cells, has been
investigated extensively as an in vivo marker of apoptosis [15–17],
although annexin V also detects necrotic cells [18]. However, the
small size and shortbiologic half-life ofannexin V limititsutilityas a
marker of therapy response. Moreover, earlier clinical development
of radiolabeled annexin V (as ApomateH) was stalled because a one-
to-one correspondence between
99mTc- 6-hydrazinopyridine-3-
carboxylic acid-(HYNIC)-annexin V uptake and radiologic re-
sponse to cancer chemotherapy was not found [19].
Notwithstanding the importance of apoptosis as a mode of
cancer cell death [20], the response of carcinomas to antineoplas-
tic treatment commonly takes days to weeks and may derive
significant contributions from other processes such as necrosis,
autophagy, mitotic catastrophe, and cell senescence [21,22].
Irrespective of the pathway to tumor cell death, dead cells remain
a common feature of many malignancies [23,24], and may
increase in number after primary chemotherapy [25,26] despite
evasion of apoptosis being recognized as a hallmark of cancer [1].
Recently, the view has emerged that defective ‘waste disposal’,
which is the phagocytic clearance of dead cells, contributes to the
generation of autoantibodies including those with La/SSB
specificity in systemic autoimmune diseases [27]. Similarly,
inefficient and/or saturated clearance mechanisms may produce
in tumours an excess of dead cells, which have lost cell membrane
integrity allowing purposeful entry of diagnostic or therapeutic
antibodies [28].
Recently, we discovered that a La-specific monoclonal antibody
(mAb) behaved as a malignancy-associated cell death ligand that
preferentially binds apoptotic malignant cells [29]. During apopto-
sis, the La antigen translocates from nucleus to cytoplasm [30], and
is fixed in dying cells by transglutaminase 2 (TG2) [29]. As cell
membrane integrity is lost during the late phase of apoptosis,
cytoplasmic La becomes accessible to binding by specific mAb,
which in turn becomes crosslinked in the dying cell by TG2 so that
its levels arehigherthan indead cells of the counterpartprimarycell
type [29]. Studies in EL4 tumor-bearing mice show that, after
cytotoxic chemotherapy, binding of this La-specific mAb to tumors
was specific and saturable with low accumulation in normal organs
[31]. The La-specific DAB4 clone, which is represented by the
APOMABH trademark, originated from a murine autoantibody
[32]. The antigen-binding domain of DAB4 has been cloned,
sequenced, expressed, and found to bind with low nanomolar
affinity to a La epitope, which is highly conserved between humans
and rodents (Al-Ejeh et al., unpublished data).
Selective in vivo targeting of La favors two major applications of
this technology in cancer diagnosis and treatment. First, La-
directed radioimmunoscintigraphy may detect early tumor
responses to antineoplastic treatment particularly with DNA-
damaging drugs and ionizing radiation. Second, La-directed
radioimmunotherapy may act by radiation-induced bystander
killing of neighboring tumor cells and may be enhanced by
radiosensitizing drugs. Here, we describe in vivo studies in which
we use radioimmunoscintigraphy to show that tumor accumula-
tion of an optimally prepared immunoconjugate of the La-specific
mAb, DAB4 [33], correlates not only with biomarkers of tumor
cell apoptosis but also with extended survival of tumor-bearing
mice after escalated doses of chemotherapy.
Methods
Ethics statement
The Animal Ethics Committee of the Institute of Medical and
Veterinary Sciences gave approval for use of the mice. In the use
and care of the mice, we followed the humane research principles
of replacement, reduction and refinement endorsed by the
National Health and Medical Research Council of Australia.
Replacement was not possible because there were no alternative
techniques to tumor-bearing mice. We achieved a reduction in the
numbers of animals used through improved experimental design.
Refinement of procedures to improve the welfare of the animals,
such as use of analgesics, avoiding significant adverse effects, and
enhanced housing conditions, were adopted.
Antibody production, purification and radiolabeling
Protein-G-purified murine mAb from cultures of La-specific
DAB4 (IgG2ak) or control Sal5 (isotype-matched) hybridomas
[29,31] were conjugated to 1,4,7,10-tetraazacyclododedane-
N,N9,N0,N--tetraacetic acid mono-(N-hydroxysuccinimidyl)
(DOTA-NHS) ester and radiolabeled with Indium-111 (
111In)
[31,33]. Radioactivity was measured using the Cobra 5010 gamma
counter (PerkinElmer Inc., Wellesley, MA), which was normalized
for Indium-111 counting using a 100–350 keV counting window.
F(ab)2 fragments were prepared using agarose-immobilized pepsin
according to the manufacturer’s instructions (Pierce, IL).
EL4 lymphoma model
We adopted the well-characterized EL4 lymphoma model of
apoptosis induction [34] with modifications as described [31].
Briefly, 10
6 EL4 cells were inoculated subcutaneously in the right
flank of 6–8 week-old syngeneic C57BL/6 (B6) mice.
Biodistribution studies
C57BL/6 mice with 1 week-old EL4 tumor implants were
untreated or given 25 mg/kg cyclophosphamide and 19 mg/kg
etoposide (full-dose chemotherapy) by intraperitoneal injection
(IPI).
111In-DOTA-DAB4 was given by intravenous injection (IVI)
via the tail vein to tumor-bearing mice with or 24 h after
chemotherapy, and an organ assay was performed [31]. Briefly,
radioactivity in counts per minute (cpm) of harvested organs was
divided by the mass to give cpm/g. Then, organ accumulation was
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was calculated as the percentage of mass-normalized counts to the
total counts (cpm) of
111In-DOTA-DAB4 at time 0.
Scintigraphic imaging of EL4 tumors
111In-DOTA-DAB4 was administered i.v. (24 h after chemo-
therapy) to each of the following groups of mice: no chemotherapy
- control mice with 4 day-old EL4 tumor implants; half dose
chemotherapy - mice with 5 day-old EL4 tumor implants; and full
dose chemotherapy - 7 day-old EL4 tumor implants. This protocol
allowed for comparison of animals with size-matched tumors, a
methodology that mimics clinical practice. Mice were euthanized
by asphyxiation following anesthetic overdose. At 48 h after
radioligand injection, whole body static images were acquired for
18 min. using a scintigraphic gamma camera (Starcam 300 M;
GE, USA). After imaging, organ assays were done [31]. The same
procedure was used for
111In-labeled F(ab)2 fragments in separate
experiments, except that D-lysine (40 mg/mL saline) was
administered 30 min. before radiotracer injection, and then every
1 h thereafter for a total of 5 injections [35].
Survival analysis
EL4-tumor bearing mice were grouped as untreated control, or
treated with half-dose or full-dose chemotherapy. Bidimensional
tumor measurements using calipers were made every second day,
and tumor volume was calculated using the formula: largest
diameter6[shortest diameter]
2/2. Mice were euthanized by
cervical dislocation when tumors reached 500 mm
3. Kaplan-
Meier plots were used to derive the median survival time using
software (GraphPad Prism v.4.0).
Ex vivo studies on EL4 tumors
Tumors were finely minced with scissors into pieces ,10 mm
3,
and a weighed proportion (0.1 g) of tumor mince was suspended in
collagenase Type 1 in Hanks’ Buffered Salt Solution (HBSS)
(10 mL; 2 mg/mL) containing 2.5 mM Ca
2+. Suspensions were
incubated at 37uC with constant rotation for 1 h. Digested tumor
cell suspensions were passed sequentially through a series of
needles (in order of 19G, 23G, and 25G) to remove coarse
materials, and then the last filtrate was centrifuged at 3506g for
5 min. Pellets were washed with HBSS (10 mL), resuspended in
HBSS (1 mL), and aliquots (100 mL) stained for 30 min. at room
temperature (RT) in duplicate with either Sal5 or DAB4 (5 mg/
mL). Cells were washed twice with phosphate buffered saline
(PBS), and incubated with rabbit anti-mouse IgG Alexa488
antibody (2 mg/mL) for 30 min. at RT in the dark. Cells were
washed thrice with PBS, resuspended in 7-Amino-Actinomycin D
(7-AAD) (2 mg/mL), and analyzed 10 min. later using a FACScan
(BD Biosciences, San Jose, CA).
Apoptosis was detected in tumors by immunohistochemical
analysis of caspase-3 activation and cleavage of poly ADP-ribose-1
(PARP-1). EL4 tumor-bearing mice were either untreated (control)
or treated with half- or full-dose chemotherapy. At 0, 24, 48 and
72 h, tumors were fixed in 10% formalin in PBS, bisected, then
each half was embedded in paraffin and sectioned. Sections were
stained with hematoxylin and eosin (H&E) or rabbit IgG raised
against either activated caspase-3 (1 mg/mL, Chemicon-Millipore,
MA) or cleaved PARP-1 (1:100 of stock, Promega, WI), and
subsequently stained with biotin-conjugated anti-rabbit IgG
antibody (1 mg/mL; Rockland Inc., PA) followed by streptavi-
din-horse radish peroxidase (HRP) (1 mg/mL). Entire sections
were scanned using the DotSlide acquisition program (Soft
Imaging System, Olympus, Tokyo, Japan) on a DotSlide BX51
Olympus light microscope (Olympus) at 206magnification.
Scanned tumor sections were visualized using OlyVIA (Olym-
pus Viewer for Imaging Applications) software, and images of
entire sections or 6 random regions at 106or 206were obtained
for analysis using analySISH software (Soft Imaging System,
Olympus). Phase color analysis was performed for all images using
pixels to define the different phases: viable cells were defined by
blue-counterstained nuclei, apoptotic cells were defined by brown
staining from 3, 39-diaminobenzine (DAB) deposition, and
necrotic areas were defined as faint blue areas, which lacked
appropriate nuclear morphology. For counting of necrotic cells,
and activated caspase-3
+ and cleaved PARP-1
+ cells, tumors were
bisected, and two images were captured from each tumor section
to generate a total of 8 images from each tumor. In each case,
numbers of necrotic, activated caspase-3
+ and cleaved PARP-1
+
cells were divided by the number of viable cells, and then
expressed as percentages.
Co-localization studies of tumor-bound DAB4, activated
caspase-3 and cleaved PARP-1 were based on immunofluores-
cence detection. Mice were given 100 mg DAB4-biotin or 100 mg
Sal5-biotin (negative control) i.v. 24 h after chemotherapy, and
tumors were dissected 24 h later. Tumor-bound DAB4-biotin was
detected by confocal microscopy using streptavidin-Alexa488
(1 mg/mL). Activated caspase-3 and cleaved PARP-1 were
detected using specific rabbit IgG followed by Alexa546-conjugat-
ed goat anti-rabbit IgG (2.5 mg/mL, Molecular Probes-Invitro-
gen, CA). Stained tumor sections were mounted using ProLong
Gold antifade reagent (Molecular Probes), and slides were
analyzed using an Olympus confocal microscope (Bio-Rad;
Hercules, CA) with appropriate filters and under constant
conditions of laser voltage, iris aperture, and photomultiplier
tube amplification.
Statistical analysis
Statistical analysis was performed with GraphPad Prism v4.0
software. Unless otherwise stated, intergroup comparisons were
made by two-way analysis of variance (ANOVA), with p,0.05
being considered significant. Kaplan-Meier median survival curves
were compared using log-rank Mantel-Cox test, with p,0.05
being considered significant.
Results
Effects of chemotherapy on biodistribution of
111In-
DOTA-DAB4 in EL4 lymphoma bearing mice, schedule,
and antigen specificity
Previously, we reported antigen-specific and chemotherapy-
dependent accumulation in EL4 lymphomas of
111In-labeled La-
specific mAb, which was injected immediately after chemotherapy
[31]. Now, we find that when
111In-DOTA-DAB4 was injected
24 hours after chemotherapy, it accumulated more rapidly in EL4
tumors as it cleared more quickly from blood (Figure 1). In EL4
tumor-bearing mice, the blood clearance half-life of
111In-DOTA-
DAB4 was 19.860.2 hours (Figure 1A), which was unchanged
(19.860.3 hours) by giving
111In-DOTA-DAB4 immediately after
chemotherapy (Figure 1B). In contrast, giving
111In-DOTA-DAB4
24 hours after chemotherapy accelerated its blood clearance with
a half-life of 9.260.1 hours, and significantly hastened its tumor
accumulation with a half-life of 4.160.2 hours compared with
18.660.3 hours if
111In-DOTA-DAB4 was injected immediately
after chemotherapy (P,0.001) (Figure 1C).
Similarly, administering
111In-DOTA-DAB4 immediately after
chemotherapy did not alter its uptake in normal organs compared
with the same uptake in control mice. In contrast, giving
111In-
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organ uptake to levels significantly lower than in control mice
(see Figure S1 online).
Comparisons of tumor accumulation of
111In-DOTA-DAB4
with fluorocytometric analysis of tumor cell death and ex
vivo tumor cell binding of DAB4
To examine the effect of chemotherapy on the frequency of EL4
tumor cell death and the intensity of ex vivo binding of DAB4 to
dead tumor cells, we analyzed single tumor cell suspensions, first
from control tumors. Here, the frequency of dead 7-AAD
+ cells
increased moderately over 96 hours (Figure 2A) whereas per cell
ex vivo binding of DAB4 increased marginally (Figure 2B). In
contrast, chemotherapy not only markedly increased the frequency
of dead tumor cells (Figure 2A) but also produced a cumulative
increase in DAB4 binding to each dead tumor cell (Figure 2B), and
suggested that DNA-damaging drugs induced tumor cell expres-
sion of La in vivo.
Intratumoral accumulation of the DAB4 mAb itself was
determined after correction for the physical decay of Indium-
111. In control tumors during the 96-hour observation period, the
frequency of dead 7-AAD
+ cells increased from 2663t o4 6 62%
(Figure 2A) in parallel with the increase in DAB4 tumor
accumulation from 1761t o3 4 64% of the injected dose per
gram of tumor tissue (see Figure S2 online). In contrast, at 72–
96 hours after chemotherapy, tumor accumulation of DAB4
reached a plateau at approximately 75–80% of the injected dose
per gram of tumor tissue (Figure 2C). However, tumor
accumulation of DAB4 tended to track the extent of ex vivo
binding of DAB4 (Figure 2D) rather than reflect the frequency of
tumor cell death (Figure 2C).
Immunohistochemical analysis of EL4 tumor caspase-3
activation and PARP-1 cleavage and
immunofluorescence analysis of in vivo tumor binding of
DAB4
Chemotherapy induced dose-dependent caspase-3 activation
and PARP-1 cleavage in tumors of EL4 lymphoma-bearing mice
(Figure 3). Immunohistochemical analysis indicated that tumor
activation of caspase-3 became most evident 24 hours after a full
dose of chemotherapy (Figure 3A) whereas PARP-1 cleavage was
best identified 96 hours post-chemotherapy (Figure 3B). Imaging
software and phase color analysis were used to quantify these
differences (Figure 3C). For example, as control tumors grew over
96 hours, areas of central necrosis (coded black, Figure 3C)
expanded in tandem with the increased control tumor content of
7-AAD
+ cells (Figure 2A). Next, we investigated the physical
relationship between stages of apoptosis and the in vivo binding to
apoptotic EL4 tumor cells of DAB4, which was antigen specific
(data not shown). In this experiment, tumor-bearing mice were
given injections of DAB4-biotin 24 hours after chemotherapy, and
tumors were harvested for immunofluorescence analysis 24 hours
later (i.e. 48 hours after chemotherapy). As illustrated in Figure 3D,
DAB4 was observed to be intimately related to cell remnants
containing cleaved PARP-1 rather than activated caspase-3,
suggesting that DAB4 mainly bound EL4 tumors via its binding
of late apoptotic cells.
Gamma camera imaging of EL4 tumor uptake of
111In-
DOTA-DAB4 after chemotherapy
The tumor response to chemotherapy was evaluated using c-
scintigraphy of the radiotracer in untreated mice and mice treated
with half- or full-dose chemotherapy. To simulate a clinical
scenario, tumor growth was staggered to match tumor sizes
(Figure 4A) so that mean values for tumor volume or weight
among the experimental groups were not significantly different. As
clinical gamma camera images of size-matched tumors of control
Figure 1. Effects of schedule of radioligand injection on
biodistribution of
111In-DOTA-DAB4 in mice bearing EL4
lymphoma. Biodistribution of
111In-DOTA-DAB4 in EL4 tumor-bearing
mice (n=5/group), which were A, untreated, or B and C, treated with
Chemo (19 mg/kg etoposide and 25 mg/kg cyclophosphamide i.p.i.),
and given i.v.
111In-DOTA-DAB4 A, alone, B, immediately after Chemo,
or C, 24 h after Chemo. At 0, 3, 24, 48, and 72 h post-
111In-DOTA-DAB4,
organ assays were used to calculate mean percentage of injected dose
per gram of tissue (%ID/g; as described in Methods). Indicated are
regression coefficient (r
2) values for curves fitted to clearance and
accumulation data using one-phase exponential decay and association
models, respectively. Blood clearance and tumor accumulation were
accelerated by delaying i.v.
111In-DOTA-DAB4 until 24 h post-chemo.
Error bars for all graphs; 6SEM.
doi:10.1371/journal.pone.0004558.g001
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111In-
DOTA-DAB4 (given 24 hours after chemotherapy) increased as
the chemotherapy dose increased. These visual data correlated
both with the quantitative biodistribution data (Figure 4C) and the
semi-quantitative planar estimate of radioactivity (inset, Figure 4C).
Chemotherapy-induced tumor targeting of
111In-DOTA-DAB4
was not a passive phenomenon because both c-scintigraphy and c-
counting showed that the isotype control,
111In-DOTA-Sal5,
accumulated significantly less in tumors irrespective of the use of
chemotherapy (Figure 4D).
Comparisons of indices of tumor cell apoptosis with
tumor accumulation of
111In-DOTA-DAB4 and survival of
EL tumor-bearing mice
Immunohistochemical and phase color analyses of tumor
sections (Figure 3) were used to derive indices of early or late
apoptosis (Figure 5) and of necrosis (see Figure S3 online). After
full-dose chemotherapy, the early apoptotic index marked by
caspase-3 activation peaked at 4.5%, 24 hours post-chemotherapy
(upper panel, Figure 5A), the late apoptotic index marked by
PARP-1 cleavage peaked at 35–40%, 48–96 hours post-chemo-
therapy (upper panel, Figure 5B), whereas the necrotic index
remained at 15–20% during the same 48–96 hour period (see
Figure S3 online). As caspase-3 activation is early and transient, a
cumulative early apoptotic index was determined as the area
under the curve generated from results of individual caspase-3
activation assays. Peak EL4 tumor accumulation of
111In-DOTA-
DAB4 (at 72 hours post-chemotherapy), which was measured as
imaged or counted gamma radioactivity, correlated directly with
both the cumulative early apoptotic (lower panel, Figure 5A) and
late apoptotic indices (lower panel, Figure 5B) but correlated
inversely with the necrotic index (see Figure S3 online). The
survival of EL4-tumor bearing mice also directly depended on
chemotherapy dose so that doubling the dose of chemotherapy
significantly extended the survival of tumor-bearing mice
(Figure 5C upper panel). Moreover, just as tumor gamma counts
from
111In-DOTA-DAB4 accumulation correlated directly with
indices of apoptosis so the counts correlated directly with the
median survival time of treated mice (lower panel, Figure 5C).
Gamma-scintigraphic detection of tumor apoptosis in
vivo using fragments of DAB4
Antibody fragments are often used as imaging probes because
washout of the probe is sufficiently slow to allow tumor
accumulation but rapid enough to provide an adequate tumor
to background ratio [36]. Accordingly, our earlier studies
demonstrated that the
111In-labeled F(ab)2 fragment of the La-
specific mAb generated a higher tumor to blood ratio than the full-
length mAb because of its faster blood clearance. As shown in
Figure 6, the response of EL4 tumors to chemotherapy was
specifically detected using DAB4-F(ab)2, and the co-injection of D-
lysine significantly lowered renal uptake. Static images indicate
Figure 2. Comparison of cell death, ex vivo and in vivo DAB4 accumulation in EL4 lymphoma model. EL4 tumor-bearing mice were
untreated (Control) or treated with 19 mg/kg etoposide and 25 mg/kg cyclophosphamide i.p.i. (Chemo) (n=3/group). Single cell suspensions were
prepared from tumors and stained in duplicate with 7-AAD alone, or with 7-AAD and Sal5 or DAB4. Fluorocytometric analysis revealed levels of tumor
cell death (%7-AAD
+ cells) and of DAB4 binding to 7-AAD
+ dead tumor cells. A, mean %7-AAD
+ (6SEM) tumor cells, *** P,0.001 versus control. B, La-
specific binding to 7-AAD
+ tumor cells was measured as net mean fluorescence intensity (MFI) (6SEM) of DAB4 binding after subtraction of MFI for
Sal5 binding,* P,0.05, *** P,0.001 versus control. C and D, in a separate study, in vivo tumor accumulation of DAB4 mAb itself (as %ID/g) was
calculated after correction for physical radio-decay of Indium-111 and plotted against values either for C, %7-AAD
+ tumor cells or D, ex vivo binding
of DAB4 to 7-AAD
+ tumor cells.
doi:10.1371/journal.pone.0004558.g002
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increased by co-administration of D-lysine, which reduces renal
tubular reabsorption of antibody fragments (Figure 6A). These
data were confirmed by measurement of gamma counts in an
organ assay (Figure 6B&C).
Discussion
Our results indicate that the DAB4 mAb, which binds the
RNA-binding protein La/SSB, accumulates selectively in tumors
after tumor-bearing mice are treated with cytotoxic chemother-
apy. We have previously proposed that nuclear RNA-binding
proteins contained within apoptotic cancer cells may be useful
molecular targets for cancer diagnosis or therapy [29]. This
hypothesis is based on the abundance and overexpression of this
class of protein in malignant cells as well as their retention and
accessibility during apoptosis [37–39]. In vitro studies showed that
the ubiquitous and exceedingly abundant ribonucleoprotein, La/
SSB [40], which is essential for early mammalian development
[41], has properties that distinguish it from other cytoplasmic and
nuclear antigens during the malignant cell death caused by DNA-
damaging treatment [29]. La acts as a molecular chaperone for
transfer and ribosomal RNA species generated by RNA
polymerase III, which is overactive in malignancy [42]. In
addition, La may be involved in coupling of transcription and
translation [43]. We discovered that La is overexpressed in
malignancy and actively induced in apoptotic malignant cells in
response to DNA-damaging treatment [29]. La overexpression in
malignancy is consistent with the increased ribosomal biogenesis
and protein synthesis that are invariant features of malignancy
[44], and associated with overexpression of RNP in the nucleolus,
the ribosome factory of the cell [45].
Other properties of the La antigen may also help to explain its
identification as a specific marker of tumor apoptotic response.
During DNA-damaging treatments such as cisplatin [29] and c-
radiation (Al-Ejeh et al., unpublished observations), higher levels of
La antigen are detected and co-localize with the cH2AX marker
of DNA double-stranded break formation in malignant cells in
vitro [29], suggesting that La is involved in early DNA-damage
responses. Interestingly, in support of the claim that La-specific
antibody detects cells dying as a result of DNA-damage,
immunofluorescence was not a sensitive enough technique to
detect binding of this La-specific mAb to spontaneously apoptotic
LNCaP prostatic carcinoma cells in vivo [46]. In contrast, we
found that La-specific mAb specifically accumulates in DNA-
damaged and dying human cancer cell lines in a time- and dose-
dependent manner. Lastly, La antigen is crosslinked in dead
malignant cells by transglutaminase 2, and this protein crosslinking
extends to include fixation of the La-bound mAb itself so that its
levels are higher than in dead primary cells [29].
The EL4 lymphoma model was chosen because cyclophospha-
mide/etoposide treatment induces robust tumor apoptosis [34].
The results from our kinetic studies indicate that chemotherapy
itself did not affect the blood clearance half-life of
111In-DOTA-
Figure 3. Effects of chemotherapy on caspase-3 activation and PARP-1 cleavage in EL4 tumors. Mice (n=3/group) were untreated
(Control) or treated i.p. with 9.5 mg/kg etoposide and 12.5 mg/kg cyclophosphamide (Half chemo) or 19 mg/kg etoposide and 25 mg/kg
cyclophosphamide (Full chemo). Formalin-fixed paraffin-embedded tumor sections were prepared for immunohistochemical detection and phase
color analysis. Shown are representative photomicrographs at 24 h or 96 h post-chemo of A, activated caspase-3, and B, cleaved PARP-1. C, shown
are representative images of phase color analysis, which are pseudo-colored: viable cells (red); necrotic cells (black); activated caspase-3
+ (green). D,
representative confocal fluorescence microscopy images of EL4 tumor sections from n=3 mice showing co-staining of DAB4 (green) and (left-hand
panels) activated caspase-3 (red) or (right-hand panels) cleaved PARP-1 (red) 24 h after i.v. biotinylated DAB4, which in turn was given 24 h after full
chemo. Scale bar, 20 mm. DAB4 localized with late apoptotic cells.
doi:10.1371/journal.pone.0004558.g003
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PLoS ONE | www.plosone.org 7 February 2009 | Volume 4 | Issue 2 | e4558DAB4 in tumor-bearing mice. Therefore, it is unlikely that
chemotherapy resulted in significant shedding of the DAB4 target
antigen into the blood of tumor-bearing mice. However, the
administration of
111In-DOTA-DAB4 24 hours after chemother-
apy did significantly accelerate the rate of DAB4 tumor
accumulation, which may have resulted in the enhanced clearance
of DAB4 from blood and normal organs. The increased tumor
binding of
111In-DOTA-DAB4 is proposed to have resulted from a
significant increase in the number and strength of DAB4 binding
targets, which was related to both the post-chemotherapy number
of dead tumor cells as well as the extent to which the La
autoantigen was induced in each dying cell.
The immunohistologic analyses defined the dynamics of the
apoptotic response of EL4 tumors to chemotherapy. Caspase-3
activation occurred within the first 48 hours of treatment, and
peaked 24 hours post-chemotherapy. Subsequently, the level of
caspase-3-mediated cleavage of PARP-1 reached a maximum
96 hours post-chemotherapy, which is when ex vivo binding of
DAB4 to dead EL4 cells was maximal.
Both caspase-3 activation and PARP-1 cleavage as early and
late markers of apoptosis, respectively, increased directly as a
function of chemotherapy dose. However, after full-dose chemo-
therapy, fewer than 5% of tumor cells contained activated caspase-
3, whereas cleaved PARP-1 was detected in up to 40% of tumor
Figure 5. Graphical comparisons of apoptotic indices, tumor accumulation of DAB4, and survival of tumor-bearing mice. EL4 tumor-
bearing mice were untreated (Control) or treated with half- or full-dose chemotherapy. Early and late apoptotic cells were identified in tumor sections
by staining for activated caspase-3 and cleaved PARP-1, respectively. Using phase color analysis, apoptotic cells were counted and expressed as a
percentage of viable cell number to create an apoptotic index. Upper row of panels show time courses of A, early apoptotic index, and B, late
apoptotic index, or C, Kaplan-Meier survival analysis of control mice and treated mice (** P,0.01 for half-dose chemotherapy versus control, * P,0.05
half-dose chemotherapy versus full-dose chemotherapy). In the lower row of panels, peak tumor accumulation of DAB4, which was measured using
either gamma counting (%ID/g) or gamma camera imaging (counts/pixel) 72 h post-chemotherapy, was plotted as a function of A, the cumulative
early apoptotic index, which represented mean %(number of activated caspase-3
+ cells6h)/(number of viable cells)6SEM (n=3/group), or B, the late
apoptotic index, which represented mean %(number of PARP-1
+ cells)/(number of viable cells)6SEM at 72 h (n=3/group), or C, the median survival
time (n=5/group). Regression coefficients (r
2) for fitted lines are displayed in brackets next to each curve. Chemotherapy-induced tumor apoptosis
correlated with both tumor accumulation of DAB4 and survival of tumor-bearing mice.
doi:10.1371/journal.pone.0004558.g005
Figure 4. Effects of chemotherapy on gamma camera imaging and biodistribution of
111In-DOTA-DAB4 in EL4 lymphoma-bearing
mice. A, as described in Methods, growth of EL4 tumors in untreated control mice was staggered so that tumor sizes matched those in mice treated
with half- or full-dose chemotherapy. B, representative clinical gamma camera images (arrow, tumor; asterisk, central blood pool) of n=3 mice. Mice
bearing size-matched EL4 tumors were untreated (Control) or given i.v.
111In-DOTA-DAB4 24 h after 9.5 mg/kg etoposide and 12.5 mg/kg
cyclophosphamide (Half chemo) or 19 mg/kg etoposide and 25 mg/kg cyclophosphamide i.p.i. (Full chemo) and 48 h later, mice were imaged. C,
chemotherapy dose effects on biodistribution of
111In-DOTA-DAB4 72 h post-chemotherapy. Mice bearing size-matched EL4 tumors were treated as
described in B, given i.v.
111In-DOTA-DAB4 24 h after chemotherapy, and 48 h later, killed for gamma counting of tumors and organs (n=3/group).
Accumulation of DAB4 is shown as mean %ID/g (6SEM). As indicated, Chemo induced significant dose-dependent tumor accumulation of
111In-
DOTA-DAB4 (P,0.001 versus Control). Inset, graph depicts mean counts/pixel (6SEM) after region of interest (ROI) analysis of the imaged mice (n=3/
group). ROI were drawn around tumors, and the gamma camera-detected counts, which were obtained using image acquisition software, were
divided by the ROI area measured in pixels; **, P,0.01, ***, P,0.001 versus other treatments as indicated. D, biodistribution of
111In-DOTA-DAB4 and
111In-DOTA-Sal5 72 h post-chemotherapy. EL4 tumor-bearing mice (n=3/group) were given i.v.
111In-labeled Sal5-DOTA or DAB4-DOTA without
chemo (Control) or 24 h after Full chemo. Gamma radioactivity was imaged as described in B, and counted as described in C, 48 h after radioligand
administration. Inset, representative clinical gamma camera images (arrow, tumor; asterisk, central blood pool). Tumor accumulation of DAB4 was
antigen-specific irrespective of Chemo use (p,0.001 versus Sal5).
doi:10.1371/journal.pone.0004558.g004
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the rapid and transient activation of caspase-3 after cytotoxic drug
treatment or ionizing radiation in vitro (data not shown). These
studies illustrate the difficulty of capturing in vivo the dynamic
elements of the apoptotic process such as caspase-3 activation, a
difficulty that is manifest clinically. For example, frequent invasive
sampling of tumor tissue was required to demonstrate that
increases in apoptotic index predicted pathologic responses of
breast cancer to neoadjuvant chemotherapy [25,26].
Scintigraphic imaging of control and treated mice indicated that
tumor accumulation of
111In-DOTA-DAB4 was influenced by the
chemotherapy regimen in a linear dose-dependent manner. In
stark contrast, the chemotherapy had no significant effect on the
radioligand distribution to harvested organs. After chemotherapy,
although the significantly greater tumor accumulation of
111In-
DOTA-DAB4 than
111In-DOTA-Sal5 indicated the antigen-
specific nature of antibody tumor targeting, twice as much of
the injected dose of
111In-DOTA-Sal5 accumulated in the tumors
of treated mice than untreated mice. However, similar observa-
tions were not made for the F(ab)2 fragments of Sal5, which
suggests that the non-specific tumor accumulation of Sal5 IgG
after chemotherapy may be Fc-dependent.
Tumor accumulation of DAB4 was linearly related to the
increase in cleaved PARP-1 within EL4 tumors. Furthermore,
biotinylated DAB4 injected into treated mice localized best in EL4
cell remnants associated with cleaved PARP-1. Given that tumor
accumulation of DAB4 most directly reflects pathologic markers of
late rather than early apoptosis, we argue that
111In-DOTA-DAB4
is a specific radioligand to detect the enduring tumor response to
effective DNA-damaging chemotherapy.
The results also demonstrate that the highest dose of
chemotherapy resulted in the highest tumor accumulation of
radioligand, and this dose ultimately extended the survival of
tumor-bearing mice. Therefore, we infer that a diagnostic
radioligand such as
111In-DOTA-DAB4 can predict the survival
of tumor-bearing mice after DNA-damaging and apoptosis-
inducing chemotherapy.
Finally, as useful imaging agents require a high tumor to
background ratio, we conducted scintigraphic and organ assays of
111In-labeled F(ab)2 fragments of DOTA-DAB4. Whole IgG
versions of radioligands tend to have protracted blood pool activity
and reduced tissue penetration whereas the shorter circulatory half
life and increased tissue penetration of antibody fragments may
produce more effective imaging agents. The results indicate that
although tumor accumulation of F(ab)2 fragments of DAB4 was
both antigen specific and chemotherapy dose-dependent, the
circulatory half life, residence time in normal organs, and absolute
levels of tumor accumulation of radiolabeled DAB4 fragments all
significantly diminished in comparison with the parental DAB4
mAb. Nevertheless, protein engineering techniques together with
modifications in the schedule of radioligand administration may be
used to optimize the imaging performance characteristics of DAB4
fragments and ensure efficient therapy monitoring.
We found that giving
111In-DOTA-DAB4 24 hours after
chemotherapy significantly reduced its normal organ accumula-
tion. This observation may be explained by the enhanced tumor
uptake of
111In-DOTA-DAB4 seen 24 hours after chemotherapy
resulting in its accelerated blood clearance, and thus the
diminished blood pool of
111In-DOTA-DAB4 available to bathe
normal organs. Hence, we believe that scheduling the injection of
111In-labeled DAB4 fragments at least 24 hours after cytotoxic
chemotherapy maximizes the opportunity to obtain an effective
radioimmunoscintigraphic agent with a high tumor to background
ratio because the target for DAB4 binding may be revealed
Figure 6. Imaging and biodistribution of antibody fragments.
DOTA-conjugated F(ab)2 fragments of Sal5 or DAB4 were
111In-labeled
and given i.v.i. to untreated (control) or treated EL4 tumor-bearing mice
24 h after full-dose chemotherapy. Some mice receiving F(ab)2
fragments also received regular D-lysine injections. Mice were imaged
with a gamma camera 24 h after radioligand administration, and then
killed to measure gamma counts in tumors and normal organs. A,
shown are representative gamma camera images of n=3 mice.
Accumulation of radioligand is shown as mean %ID/g6SEM (n=3/
group) for F(ab)2 forms of Sal5 and DAB4 B, without or C, with co-
injection of D-lysine at 24 h (* P,0.05, ** P,0.01, *** P,0.001 for DAB4
versus Sal5). Antigen-specific and chemotherapy-dependent tumor
accumulation of DAB4 occurred independently of the Fc fragment.
doi:10.1371/journal.pone.0004558.g006
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tissues. As was discovered in the jejunal apoptosis model,
chemotherapy-induced apoptosis in normal tissues runs a shorter
(24–36 hour) time course [47] than the several days (at least)
apparent in malignant tissues [21]. Differences in the time course
of chemotherapy-induced apoptosis between normal and malig-
nant tissues may happen in part because phagocytosis of apoptotic
cells is efficient in normal tissues [48] but inefficient in malignant
tissues because an excess of apoptotic cells seems to overwhelm
clearance mechanisms [23].
In vivo measurements of cell death, proliferation, metabolism
and hypoxia in a multi-parametric design may hold higher
prognostic and predictive value than single measurements and
could provide surrogates for clinically meaningful endpoints [2].
Ideal cancer therapy monitoring technologies are rapid, robust,
and minimally invasive. They reflect tumor heterogeneity, and
yield quantitative real-time data about biologically significant
processes like apoptosis.
In conclusion, as a late apoptotic malignant cell-death ligand,
the La-specific DAB4 mAb detected the heightened and enduring
tumor cell-death response resulting from DNA-damaging treat-
ment. Thus, these preclinical data encourage future development
of clinically applicable imaging methods for the detection of DNA
damage-related tumor cell death arising from treatments such as
cytotoxic chemotherapy and ionizing radiation.
Supporting Information
Figure S1 Delaying the injection until 24 hours after chemo-
therapy accelerated the blood clearance and tumor accumulation
of the radioligand. B6 mice bearing syngeneic EL4 tumors were
untreated or treated with full-dose chemotherapy, and given
intravenous injections of
111In-DOTA-DAB4 alone (clear col-
umns), immediately after chemotherapy (striped columns), or 24 h
after chemotherapy (filled columns). Mice were killed at A, 3, B,
24, C, 48, and D, 72 h after injection of
111In-DOTA-DAB4 to
measure its accumulation in blood, normal organs and tumors,
which was calculated as the percentage of mass-normalized counts
per minute (cpm) to total cpm of the injected dose at time 0 (%ID/
g). Data shown are mean %ID/g6SEM (n=5), * P,0.05, **
P,0.01, and *** P,0.001 versus control mice (2-way ANOVA).
Found at: doi:10.1371/journal.pone.0004558.s001 (0.05 MB
DOC)
Figure S2 Expression of La in dead cells in EL4 tumors
correlated with the accumulation of DAB4 in vivo. Single tumor
cell suspensions from untreated mice were stained with A, 7-AAD
alone or B, 7-AAD and Sal5 or DAB4 to determine the specific
binding of DAB4 to dead cells. In a separate study, accumulation
of DAB4 mAb itself within tumors in vivo was calculated using
values for
111In-DOTA-DAB4 accumulation after correction for
physical radio-decay of Indium-111. Tumor accumulation of
DAB4 as %ID/g was plotted against A, tumor cell death measured
using 7-AAD uptake or B, the ex vivo binding of DAB4 to 7-AAD
+
dead cells.
Found at: doi:10.1371/journal.pone.0004558.s002 (0.03 MB
DOC)
Figure S3 Accumulation of
111In-DOTA-DAB4 correlated
inversely with tumor necrosis. EL4 tumor sections from untreated
(control) and treated mice were stained with H&E and phase color
analysis used to determine regions of necrosis. A, Average necrotic
index (6SEM, n=3) was calculated as the percentage of necrotic
areas to viable areas at 0, 24, 48, 72, and 96 h. B, Tumor
accumulation of
111In-DOTA-DAB4 was measured using gamma
counting (%ID/g) or gamma camera imaging (counts/pixel) and
plotted as a function of the necrotic index at 72 h.
Found at: doi:10.1371/journal.pone.0004558.s003 (0.03 MB
DOC)
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